1 Hypothesis, Multiple Implications: Adenoviral Vector Vaccines and Thrombosis with Thrombocytopenia Syndrome
The RPTH Journal (Research and Practice in Thrombosis and Haemostasis) shared an insightful post on LinkedIn:
”This new study investigates adenoviral vector vaccine-associated thrombosis/thrombocytopenia risk.
- Adenoviral vectors can infect megakaryocytes
- Concurrent infection may increase chemokine receptor expression
Senior Author: Joseph Torresi”
Read the full article here.
In the article ”Adenovirus vectors can infect mouse megakaryocytes – implications for vaccine-induced thrombosis/thrombocytopenia” by Simon Collett, Joseph Torresi et al. in the RPTH Journal, a potential role of adenoviral vector vaccines in inducing TTS is discussed.
Adenoviruses, adenoviral vector-based vaccines, and gene delivery systems have been associated with thrombosis with thrombocytopenia syndrome (TTS), a rare but serious complication.
The precise mechanisms underlying this condition remain unclear.
It was previously hypothesized that megakaryocytes (MKs)—the precursor cells responsible for platelet production—play a central role in the development of adenovirus- or vector-induced TTS.
Emerging evidence supports the notion that MKs are a heterogeneous population, including subsets with distinct immune-related functions.
This study demonstrates that adenoviral infection preferentially targets higher-ploidy CD41⁺CD42⁺ MKs and those expressing high levels of CXCR4 (CXCR4^hi).
These findings implicate specific MK subsets and surface receptors in the cellular response to adenoviral exposure and provide a potential mechanistic link to thrombocytopenia and thrombotic events observed post-vaccination or gene therapy.
Find all the latest scientific advancements in the World of Thrombosis posted in Hemostasis Today.
-
Sep 11, 2025, 08:33Alfonso J. Tafur Shares VascuLearn’s Free Virtual Support Groups This Fall for Patients and Providers
-
Sep 10, 2025, 23:00Blood Vessels, Thrombosis and Hemostasis - Blood VTH and Blood Neoplasia: Now Indexed in PubMed!
-
Sep 10, 2025, 13:00Shivani Modi Presents 7 Posters at SOHO 2025: From AI to Hematologic Emergencies
-
Sep 10, 2025, 09:27Deep Vein Thrombosis (DVT) Explained in One Slide: Causes, Symptoms, Diagnosis and Treatment
-
Sep 10, 2025, 09:20Giuseppe Biondi Zoccai Celebrates Release of New Book on Medical Statistics
-
Sep 10, 2025, 22:34Nicolas Gendron on The Emerging Role of CLIA in The Diagnosis Strategy for HIT
-
Sep 10, 2025, 21:13Gregory Piazza on The Link Between VTE and Atherothrombosis
-
Sep 10, 2025, 19:00Maria Meritxell Roca Mora: DOACs Show Promise Over VKAs in Kidney Transplant Recipients
-
Sep 10, 2025, 08:20Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
-
Sep 10, 2025, 03:36International Journal of Stroke: Rising Incidence of Stroke in Young Adults
-
Sep 9, 2025, 20:15Linking a Single Dominant Antibody to HIT: A Novel Study Led by Ishac Nazy, Donald Arnold, and John G. Kelton
-
Sep 8, 2025, 14:24Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
-
Sep 8, 2025, 02:35Reza Shojaei on the Real Worth of Hemoglobin Oxygen Carriers – HBOCs
-
Sep 7, 2025, 14:16Mary Kiige: Biological Hemoglobin Oxygen Carrier as a Lifesaving Oxygen Bridge
-
Sep 7, 2025, 14:13Breakthrough in Blood: Cécile Denis and INSERM Team Develop Nanobody Therapy for Type 1 VWD
-
Sep 11, 2025, 08:08Al-Ola A Abdallah on MGUS-Related Bleeding Disorders
-
Sep 10, 2025, 19:32Denis Brutus Oduor: Call for Altruism in Blood Donation in Nairobi
-
Sep 9, 2025, 10:34James Douketis Receives the 2025 Distinguished Service Award in General Internal Medicine!
-
Sep 9, 2025, 08:07Hemophilia Federation of America Launches ‘Blood Brothers’ Podcast for Men With Bleeding Disorders
-
Sep 9, 2025, 04:57World Thrombosis Day 2025: Louise Bannon Invites Donations and Partnerships